Overview

Ceritinib Rare Indications Study in ALK+ Tumors

Status:
Terminated

Trial end date:
2018-08-20

Target enrollment:

Participant gender:

Summary

This is Proof-of-Concept (POC) study to assess the preliminary antitumor activity and safety and tolerablity using ceritinib (LDK378) in the treatment of life threatening tumors that are characterized by ALK genetic alteration (and/or overexpression in some diseases).

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Ceritinib